Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 31676905.
- Also identified by DOI 10.1093/cid/ciz1084.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.
Medical subject headings
- Mycobacterium tuberculosis
- Nitroimidazoles
- Tuberculosis, Multidrug-Resistant